- Corporate Information
- SEC Filings
- Company News
- New Facility
NanoViricides Inc.
1 Controls Drive,
Shelton, CT 06484
Ph No:- 203-937-6137
Fax No:- 203-859-5095
Email:- info@nanoviricides.com
Welcome to NanoViricide's Investor Relations section.
NanoViricides, Inc. is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology permits direct attacks at multiple points on a virus particle. It is believed that such actions lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
We have been aggressively expanding our portfolio of virus targets and drug candidates every year since our inception in May, 2005.
May 7, 2023
EFHutton: NNVC- Inflection Point Reached of Multi-Indications Platform; Re-Initiating With a Buy and $6.50 Price Target
Dec. 13, 2023
EFHutton: NNVC- Inflection Point Reached of Multi-Indications Platform; Re-Initiating With a Buy and $6.50 Price Target Most Recent Fact Sheet
Most Recent Fact Sheet
Nanoviricides Inc Fact Sheet: Sept. 8th, 2023 June 4, 2024 - This is NHP PK profile of NV-387 which showed desirable unusually slow decline May 29, 2024 - A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More - Novel Host-Mimetic, Virus Killing Technology Platform May 23, 2024 - NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc May 20, 2024 - The RSV animal study lung histopathology results are astounding. They indicate complete cure ofRSV by NV-387 treatment. Only partial protection for some time by ribavirin treatment. May 15, 2024 - NanoViricides Has Filed its Quarterly Report - NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection May 14, 2024 - A Novel Broad-Spectrum Antiviral with Activity Against RSV – Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment May 10, 2024 - NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City May 8, 2024 - A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox – NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides May 6, 2024 - A Novel Broad-Spectrum Antiviral with Activity Against Influenza A – NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides April 30, 2024 - NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon February 15, 2024 - NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon February 1, 2024 - Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics January 29, 2024 - Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found January 4, 2024 - NanoViricides to Present at the Biotech Showcase in San Fransisco November 28, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides November 15, 2023 - NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications November 14, 2023 - Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development October 16, 2023 - NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV October 11, 2023 - NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET August 21, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides July 11, 2023 - Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model July 6, 2023 - Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs May 31, 2023 - NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET May 16, 2023 - NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin April 25, 2023 - NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient April 17, 2023 - NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate more news
- 04-15-2014 NanoViricides won the IAIR AWARD
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
- 02-20-2014Dr. Anil R. Diwan Recognized as "Researcher of the year".
NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal.
Quick Links
About Us
Board of Directors
Executive Officers
Other Officers
Scientific Advisory Board
Pipeline
Technology
Tailorable Platform Technology
Dismantling MCMV
ADIF Technology
Investor Info
Corporate Information
SEC Filling
Company News
Contact Information
NanoViricides, Inc.
1 Controls Drive,
Shelton, CT 06484
Phone: +1-203-937-6137
Phone: +1-888-591-3579
Fax: +1-203-859-5095
E-mail: info@nanoviricides.com
